Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**7-isopentenyloxycoumarin** is a naturally occurring oxyprenylated derivative of umbelliferone (coumarin), found in members of Rutaceae and Apiaceae (including medicinal and edible plants)[3][1]. It is characterized by a 3,3-dimethylallyl (isopentenyl) side chain at the 7-position of the coumarin core. Recent pharmacological research demonstrates diverse bioactivity: - **Anticancer**: Induces cell cycle arrest at G2/M, DNA fragmentation, chromatin condensation, increased caspase 3 activity (suggesting a proapoptotic effect), inhibition of tumor angiogenesis, and reduction of chemokine CCL2 release in tumor microenvironment. Shows cytotoxicity against certain tumor cell lines and can reverse multidrug resistance[1][3]. - **Neuroprotective**: Reduces activation of microglia and provides protection against dopaminergic neuronal cell death in models of neurodegeneration (e.g., Parkinson’s disease)[1][5]. - **Enzyme inhibition**: Potent inhibitor of butyrylcholinesterase (IC50 ~11.77 μM), with limited acetylcholinesterase activity, and notable π–π stacking interactions with butyrylcholinesterase active site[1]. - **Melanogenesis stimulator**: Significantly increases melanin biosynthesis via strong agonism of estrogen receptor β, upregulation of tyrosinase-related proteins, and microphthalmia-associated transcription factor; potential additional involvement with aryl hydrocarbon receptor[1]. - **Other properties**: Antigenotoxic (reduces DNA damage under oxidative stress), antibacterial, antifungal, antiprotozoal, anti-inflammatory, and antioxidant effects[3]. Toxicity studies demonstrate low toxicity and non-genotoxicity at tested doses[1]. No approved medical uses or commercial formulations are listed; studies are mainly in vitro and in vivo (nonclinical/preclinical).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-isopentenyloxycoumarin.